Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Standard of Care 6Cisplatin 6Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4toripalimab 3pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Prednisone 3Population Groups 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Poly(ADP-ribose) Polymerase Inhibitors × 1 year × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡